Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Obesity = higher cardiovascular risk. In the placebo arm, every +5 BMI units above 30 kg/m² increased MACE risk by 11%.
Benefit of evolocumab grows as BMI increases.
•BMI <30: 11% RRR, ARR 1.4%
•BMI 30–34.9: 14% RRR, ARR 1.8%
•BMI ≥35: 29% RRR, ARR 5.7%, NNT = 17 at 3 years
LDL-C lowering remains equally powerful across all BMI categories (≈–56% to –61%). Obesity didn’t blunt the lipid response.
Inflammation amplifies risk. Highest MACE rates occurred in patients with both obesity and elevated hsCRP (>3 mg/L) – and this group also derived the largest benefit from evolocumab.
Key insight: Obesity appears to create an “atherogenic + inflammatory” residual-risk phenotype that is highly modifiable with intensive LDL-C lowering.
Clinical message: For ASCVD patients with obesity – particularly those with class 2–3 obesity or high hsCRP – PCSK9 inhibition is not optional; it’s essential.
Open access.”
Title: Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER
Authors: Yu Mi Kang, Robert P. Giugliano, Anthony C. Keech, J. Antonio G. López, Maria Laura Monsalvo, E. Magnus Ohman, Xinhui Ran, Sabina A. Murphy, Marc S. Sabatine, and Michelle L. O’Donoghue
Stay updated with Hemostasis today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda